<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858857</url>
  </required_header>
  <id_info>
    <org_study_id>GAP2013</org_study_id>
    <secondary_id>V-15222/68605/2012-2015</secondary_id>
    <nct_id>NCT01858857</nct_id>
  </id_info>
  <brief_title>Geriatric Psychiatry and Pharmacovigilance</brief_title>
  <acronym>GAP</acronym>
  <official_title>Pharmacovigilance in Gerontopsychiatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Arzneimittelsicherheit in der Psychiatrie AMSP e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Fachklinikum Brandenburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Fachklinikum Lübben für Psychiatrie, Psychotherapie und Psychosomatik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Fachklinikum Teupitz für Psychiatrie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krankenhaus Hedwigshöhe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kompetenznetz TDM KJP e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational multicenter-study is to investigate safety of
      psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric
      inpatients. Elderly people are at higher risk for developing side effects under
      pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and
      often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their
      symptoms clearly, for example due to pronounced cognitive impairment.

      The aim of the study is to gain valid data of possible adverse drug reaction rates, their
      potential risk factors and outcome, as well as medical prescription practises.

      To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the
      five participating study sites.

      At Baseline demographic data, previous and present disorders, use of drugs, previous and
      present medication, quality of life, cognitive function, physical examination results,
      laboratory results and ECG will be assessed.

      Afterwards patients are visited weekly and screened for possible adverse drug reactions. All
      adverse drug reactions will be coded in the MedDRA-system.

      In case of a possible serious adverse drug reaction serum levels of all psychotropic
      substances applicated will be assessed. Drug combinations will be analysed using an
      established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible
      adverse drug reactions are documented continually.

      2 weeks after discharge from the ward, patients will be contacted by phone to assess
      catamnestic data.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of frequency and severity of adverse events in geriatric psychiatry inpatients under psychopharmacological treatment</measure>
    <time_frame>Patients will be monitored continuosly during the hospital stay (expected average of 4 weeks) and at follow-up, which is 2 weeks after discharge.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of cognitive functioning</measure>
    <time_frame>At baseline visit and last visit, max. 3 days before discharge from the ward (expected average of hospital stay: 4 weeks).</time_frame>
    <description>Mini Mental State Exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At baseline visit and last visit, max. 3 days before discharge from the ward (expected average of hospital stay: 4 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>Patients will be monitored continuosly during the hospital stay (expected average of 4 weeks) and at follow-up, which is 2 weeks after discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of substances</measure>
    <time_frame>1 day at occurence of SAE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>At baseline visit and last visit, max. 3 days before discharge from the ward (expected average of hospital stay: 4 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication intake</measure>
    <time_frame>Patients medication intake 2 weeks before hospitalisation, continuosly during the hospital stay and at follow-up 2 weeks after discharge will be assessed (expected average of 8 weeks).</time_frame>
    <description>Before hospitalisation and after discharge by interview, during the hospital stay by patients chart.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Dementia</condition>
  <condition>Depression</condition>
  <condition>Schizophrenia</condition>
  <condition>Psychosomatic Disorders</condition>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Geriatric psychiatric in patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All inpatients meeting the Inclusion/Exclusion criteria, treated at one of the geriatric
        psychiatry study sites (one university hospital and four primary care clinics), should be
        screened.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 65+ years old

          2. Inpatients treated at one of the geriatric psychiatry study sites.

          3. Signed consent form ( Patient and/or legally authorized custodian)

        Exclusion Criteria:

        1. Patients that are incapable to give their informed consent and are not under legally
        authorized custodianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helge Frieling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MHH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sermin Toto, MD</last_name>
    <role>Study Director</role>
    <affiliation>MHH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Bleich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MHH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Kleimann, MD</last_name>
    <phone>+495115326559</phone>
    <email>gap_study@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Hedwigshöhe</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beirich Susanne</last_name>
      <email>s.beirich@alexius.de</email>
    </contact>
    <investigator>
      <last_name>Hans Gutzmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachklinikum Brandenburg</name>
      <address>
        <city>Brandenburg an der Havel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Hohl-Radke, MD</last_name>
      <phone>+49 3381 782156</phone>
    </contact>
    <investigator>
      <last_name>Felix Hohl-Radke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Garlipp, MD</last_name>
      <phone>+495115326559</phone>
      <email>garlipp.petra@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Petra Garlipp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachklinikum Lübben</name>
      <address>
        <city>Lübben</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kropp Stefan, MD</last_name>
      <phone>+49 3546 29200</phone>
    </contact>
    <investigator>
      <last_name>Stefan Kropp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachklinikum Teupitz</name>
      <address>
        <city>Teupitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kropp</last_name>
      <phone>+4933766660</phone>
    </contact>
    <investigator>
      <last_name>Stefan Kropp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Helge Frieling,MD</investigator_full_name>
    <investigator_title>Professor Dr. Helge Frieling, Deputy Director of the Department of psychiatry, social psychiatry and psychotherapy</investigator_title>
  </responsible_party>
  <keyword>geriatric psychiatry</keyword>
  <keyword>pharmacovigilance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Psychophysiologic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

